@prefix dct: <http://purl.org/dc/terms/> .
@prefix this: <http://www.tkuhn.ch/bel2nanopub/RADx7guABohbRLeYxL_qdj8l5UiOFyyYccLICKSyHdG98> .
@prefix sub: <http://www.tkuhn.ch/bel2nanopub/RADx7guABohbRLeYxL_qdj8l5UiOFyyYccLICKSyHdG98#> .
@prefix beldoc: <http://resource.belframework.org/belframework/1.0/knowledge/large_corpus.bel> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix dce: <http://purl.org/dc/elements/1.1/> .
@prefix pav: <http://purl.org/pav/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix belv: <http://www.selventa.com/vocabulary/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix schem: <http://resource.belframework.org/belframework/1.0/namespace/selventa-legacy-chemical-names/> .
@prefix Protein: <http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080> .
@prefix mgi: <http://www.informatics.jax.org/marker/MGI:> .
@prefix geneProductOf: <http://purl.obolibrary.org/obo/RO_0002204> .
@prefix species: <http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=> .
@prefix occursIn: <http://purl.obolibrary.org/obo/BFO_0000066> .
@prefix pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/> .
@prefix orcid: <http://orcid.org/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubinfo;
    a np:Nanopublication .
}

sub:assertion {
  sub:_1 geneProductOf: mgi:96765;
    a Protein: .
  
  sub:_2 occursIn: species:10090;
    rdf:object sub:_1;
    rdf:predicate belv:increases;
    rdf:subject schem:serum%20insulin;
    a rdf:Statement .
  
  sub:assertion rdfs:label "a(SCHEM:\"serum insulin\") -> p(MGI:Ldlr)" .
}

sub:provenance {
  beldoc: dce:description "Approximately 61,000 statements.";
    dce:rights "Copyright (c) 2011-2012, Selventa. All rights reserved.";
    dce:title "BEL Framework Large Corpus Document";
    pav:authoredBy sub:_4;
    pav:version "1.4" .
  
  sub:_3 prov:value "Insulin plays a central role in regulation of lipid metabolism, with different sites of action. In the adipose tissue, insulin inhibits lipolysis via an inhibition of the lipase, leading to reduce the flux of free fatty acids into the circulation. Insulin inhibits the VLDL production by the liver. Insulin is a potent activator of the lipoprotein lipase, promoting the catabolism of triglyceride-rich lipoproteins (Chylomicrons, VLDL). insulin promotes the clearance of LDL. Indeed, insulin stimulates apoB/E receptor (LDL-receptor) activity and enhances LDL degradation via the LDL-receptor pathway. Insulin also plays an important role in HDL metabolism since it activates LCAT activity, it reduces PLTP activity and modulates the hepatic triglyceride lipase activity. Because of the key role of insulin in lipid metabolism, we can easily understand that all diseases with impaired insulin action, such as insulin resistance or diabetes mellitus, will be characterized by important lipid abnormalities, which are important factors responsible for the increased cardiovascular risk in the patients.";
    prov:wasQuotedFrom pubmed:11452214 .
  
  sub:_4 rdfs:label "Selventa" .
  
  sub:assertion prov:hadPrimarySource pubmed:11452214;
    prov:wasDerivedFrom beldoc:, sub:_3 .
}

sub:pubinfo {
  this: dct:created "2014-07-03T14:29:57.279+02:00"^^xsd:dateTime;
    pav:createdBy orcid:0000-0001-6818-334X, orcid:0000-0002-1267-0234 .
}